# A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery

> **NCT04089735** · PHASE2 · COMPLETED · sponsor: **Formosa Pharmaceuticals, Inc.** · enrollment: 165 (actual)

## Conditions studied

- Ocular Inflammation and Pain After Cataract Surgery

## Interventions

- **DRUG:** APP13007, 0.05%
- **DRUG:** APP13007, 0.1%
- **DRUG:** APP13007 Placebo, 0.05%
- **DRUG:** APP13007 Placebo, 0.1%

## Key facts

- **NCT ID:** NCT04089735
- **Lead sponsor:** Formosa Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-13
- **Primary completion:** 2020-04-07
- **Final completion:** 2020-04-07
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2023-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04089735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04089735, "A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04089735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*